New FDA Regulations Take Effect: Medical Device Independent Websites Must Integrate Real-Time Verification

On July 21, 2026, a new regulation of the U.S. Food and Drug Administration (FDA) officially took effect, requiring B2B medical device websites targeting the U.S. market to embed modules on product pages that can verify the real-time status of FDA 510(k) or De Novo certification. For Chinese exporters' official websites, product presentation pages targeting U.S. purchasers, and business processes related to import customs clearance, this change deserves close attention, because the compliance presentation method on websites has shifted from static explanations to real-time verification, and failure to comply may affect procurement recommendation eligibility and customs clearance procedures.

New Requirements Target Real-Time Compliance Presentation on Websites

The confirmed information indicates that the FDA officially implemented the relevant requirements on July 21, 2026. They apply to all B2B medical device websites targeting the U.S. market, including the official websites of Chinese exporters.

Under the requirements, relevant websites must dynamically embed a real-time API verification module for FDA 510(k) or De Novo certification status on product pages and support bilingual display in English and Spanish.

The verification module must connect directly to the FDA public database. Static screenshots or manual updates are not permitted. For non-compliant websites, there is a clearly identified risk of being removed from the FDA procurement recommendation directory and affecting import customs clearance.

Which Business Processes Will Feel the Changes First

Website Compliance Pressure on Exporting Companies Will Come Earlier

Based on the analysis, medical device exporters conducting business directly with U.S. customers will be affected first. The reason is that product pages are no longer merely display windows; they also perform the function of disclosing compliance information in real time. The main impacts will involve official website revisions, product page maintenance, certification status presentation, and consistency of externally disclosed information. What deserves greater attention now is whether companies can accurately associate specific products with their corresponding certification status and display the results returned in real time by the FDA public database.

Procurement and Distribution Channels Will Place Greater Emphasis on Online Verification Results

From an industry perspective, purchasers in the U.S. market, channel distribution participants, and business entities related to FDA procurement recommendations will also be directly affected. The reason is that real-time verification results on product pages may become an important reference for preliminary supplier screening and product status verification. The main impacts will involve supplier review, page verification, communication efficiency, and pre-procurement confirmation. One change to watch is that practices previously relying on screenshots, email explanations, or manually updated pages may subsequently fail to meet actual usage requirements.

Supply Chain and Customs Clearance Service Providers Need to Adjust Their Verification Practices Accordingly

Supply chain service providers and partners involved in import customs clearance also need to pay attention to this rule. The reason is not that they are directly responsible for website development, but that non-compliant websites may affect import customs clearance. The impacts are more likely to arise in document checking, pre-delivery preparation, and customer communication. Relevant participants need to note whether real-time website verification has become part of the business documentation chain and whether the information displayed on relevant pages remains consistent with the actual declaration information.

Which Practical Issues Should Companies Focus on Now

First Confirm the Scope of Application, Then Handle Page-to-Certification Correspondence

Based on the analysis, the primary task is not to interpret the rule broadly, but to confirm whether the company's own website is a B2B medical device website targeting the U.S. market and which product pages need to display the corresponding certification status. Once an external page involves procurement and transaction communications for the U.S. market, the mapping between the page and certification status becomes a key point of implementation.

Technical Implementation Must Go Beyond Static Presentation

What deserves greater attention now is that the rule clearly requires real-time API verification with a direct connection to the FDA public database. This means that static screenshots and manually updated text explanations no longer meet the requirements. During implementation, companies need to distinguish between “displaying compliance information” and “completing real-time verification in accordance with the rules” to avoid mistakenly treating a formal page update as compliance with the requirements.

Bilingual Display Will Affect Customer-Facing Communication Details

The requirement for bilingual display in English and Spanish means that companies must not only complete the technical integration but also ensure consistency in external communications. For teams that serve U.S. market customers over the long term, it will be necessary to monitor whether page information points to the same certification status in different languages and whether discrepancies exist among customer communications, document delivery, and page access.

Procurement Recommendation and Customs Clearance Risks Need to Be Included in Contingency Plans

From a practical perspective, non-compliant websites may be removed from the FDA procurement recommendation directory and may affect import customs clearance. This means that website compliance is no longer solely a matter for marketing or branding departments. Companies should focus on key products, key customers, and key shipment milestones, particularly before delivery, before customer audits, and during customs clearance preparation, and verify in advance that the page verifier is operating properly and that the displayed content is usable.

This Looks More Like a Substantive Tightening of Website Compliance Requirements

As an observation rather than an established conclusion, the signal released by this information is relatively clear: in B2B medical device transactions targeting the U.S. market, compliance statements on websites are shifting from editable content to verifiable content. This is not merely an addition of page functionality; it connects the presentation of product compliance status with the official database.

Looking further, this change is more appropriately understood as an implemented regulatory adjustment rather than merely a directional statement. However, the specific enforcement standards, page implementation details, and adaptation of different types of companies in actual business operations still require ongoing observation. There is no need for the industry to exaggerate its scope of impact, but it should not be treated as a simple technical update either.

How Should This Change Be Understood at This Stage

Overall, the core significance of this new regulation is that online presentation pages used by medical device companies for the U.S. market have been incorporated into a more direct compliance verification chain. In the short term, it represents changes in website and product information management requirements; in the medium term, it may affect procurement review and the efficiency of customs clearance coordination.

The more appropriate way to understand it is that this is not an ordinary website functionality upgrade, but a compliance action closely connected with business operations involving the U.S. market. For relevant companies and service providers, the current priority is not to speculate on excessive extended consequences, but to first confirm the scope of application, check page status, understand the real-time verification requirements, and continue monitoring subsequent official statements and implementation details.

Basis of This Article and Directions for Further Verification

This article was generated based on the information title, event date, and event summary provided by the user. The known information is limited to the effective date of the new FDA regulation, applicable entities, real-time API verification requirements, bilingual display requirements, data connection method, and the possible impact of non-compliance on procurement recommendations and import customs clearance.

Following the general verification process for this type of industry information, subsequent confirmation would normally require continued reference to official announcements, corporate announcements, industry association information, reports from authoritative media, and relevant standards or institutional documents. It should be noted that no link to a specific official source was provided in the input. Therefore, the implementation details, subsequent interpretation, and actual scope of application still require further verification and tracking.